TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06676124

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Piper crocatum Extract Cookie
Description: Participants in the intervention group will receive cookies containing a standardized 10% ethyl acetate extract of Piper crocatum, known for its antioxidant and anti-inflammatory properties. These cookies will be consumed twice daily for 12 weeks. The intervention aims to assess the effects of Piper crocatum on renal biomarkers, such as MMP-9 and NGAL, in diabetic patients with early renal dysfunction

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants in the placebo group will receive cookies that are identical in appearance, taste, and texture to the active Piper crocatum cookies but do not contain the Piper crocatum extract. These cookies will be consumed twice daily for 12 weeks, serving as a control to assess the effects of the active intervention on renal biomarkers associated with diabetic nephropathy.
Study: NCT06676306

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT06483308

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Radiotherapy using 30Gy in 6 fractions (alternate days) over 12 days.
Study: NCT06676696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue low dose calcineurin inhibitor (CNI)
Description: CNI dose (tacrolimus or cyclosporine) will be adjusted to maintain low tacrolimus or cyclosporine whole blood trough levels from month 3 to month 24 or End of Study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitor withdrawal at 6 months
Description: CNI dose (tacrolimus or cyclosporine) will be reduced to one-half on month 3 visit and completely withdrawn on month 6 visit.
Study: NCT05685316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COPLA® cartilage implant
Description: In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
Study: NCT06184152

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CEUS imaging
Description: Contrast-enhanced ultrasound (CEUS)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: aMRI imaging
Description: contrast enhanced abbreviated MRI (AMRI)
Study: NCT05086432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sputum-guided management
Description: As previously described.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: As previously described.
Study: NCT06648785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine
Description: oral fluoropyrimidine 1000mg/m2
Study: NCT04717570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foldax TRIA Mitral Valve
Description: Mitral Valve Replacement
Study: NCT06575725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT05157360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT
Description: hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline solution
Study: NCT05620472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1
Description: One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1
Description: One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1
Description: One single intravenous injection of \[99mTc\]Tc(CO)3-(HE)3-Ec1, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT05364697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IoNIR Ridaforolimus-Eluting Coronary Stent System
Description: The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
Study: NCT05500690

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid Tablet
Description: 5 mg folic acid supplement
Study: NCT05398289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-week duration of antibiotic therapy
Description: The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-week duration of antibiotic therapy
Description: The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
Study: NCT06186375

Intervention type: OTHER
Intervention: Patients with planned biotherapy
Description: Single additional volume of blood (10 ml) to be collected using the PAXgene system at the same time as the routine blood test before starting biotherapy.
Study: NCT05265819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-BOX kinetic360
Description: 1) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroid hormone replacement therapy
Description: thyroid hormone replacement therapy
Study: NCT05064748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benvitimod
Description: Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
Study: NCT05789472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Executive functions and reaction times of all participants will be measured.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Executive functions and reaction times of all participants will be measured.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Executive functions and reaction times of all participants will be measured.
Study: NCT06499584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode
Description: During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests. During the surgery, stimuli are delivered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode
Description: During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests. During the surgery, stimuli are delivered.
Study: NCT05521880

Intervention type: DRUG
Group type: OTHER
Intervention: Oritavancin
Description: Sequential therapy with weekly doses of oritavancin 1200 mg in stable, discharge appropriate patients with opioid use related invasive infections collocated in setting of treatment for opioid use disorder
Study: NCT04199728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector
Description: Liraglutide will be provided using an injection pen provided by the manufacturer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection pen
Study: NCT06259409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenn® Negative Pressure Therapy System
Description: Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena™ Incision Management System
Description: Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
Study: NCT05604885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 60 mg
Description: AP1189 tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 80 mg
Description: AP1189 tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 100 mg
Description: AP1189 tablets for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for oral use
Study: NCT05886491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDX012
Description: GDX012 suspension for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDX012
Description: GDX012 suspension for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Chemotherapy agents (fludarabine/cyclophosphamide) as per standard of care.
Study: NCT06300775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified hyrax
Description: Appliance used for rapid maxillary expansion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: quad helix
Description: device use for slow maxillary expansion
Study: NCT06315777

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cumulus cell oocytes complex (COC) among women with poor ovarian reserve
Description: level of expression of Gremlin-1 (GREM1), Hyaluronic acid synthetase-2 (HAS2), and Prostaglandin-endoperoxide synthase-2 (PTGS2) in cumulus cell oocytes complex (COC) among women with poor ovarian reserve were analyzed
Study: NCT04788836

Intervention type: OTHER
Intervention: Questionnaire (Survey and Food Frequency Questionnaire (FFQ))
Description: Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.

Intervention type: OTHER
Intervention: Collection of digital receipts from grocery shopping
Description: Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation
Study: NCT05574881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: 150 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg d1, 15, 29, and then q4w
Study: NCT05765695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation performed with a 19 gauge STARmed needle.
Description: The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
Study: NCT06016920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes.
Study: NCT05825209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Food-Grown Magnesium
Description: 1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: 1 daily dose of 2 capsules containing microcrystalline cellulose
Study: NCT05360420

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immediate CEUS
Description: Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
Study: NCT05574881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840mg q3w, and then 420 mg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg q3w, and then 6 mg/kg q3w
Study: NCT06347991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SelfBack
Description: The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
Study: NCT04905199

Intervention type: PROCEDURE
Intervention: Temporary transvenous cardiac pacing
Description: Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.

Intervention type: PROCEDURE
Intervention: Temporary transvenous cardiac pacing
Description: Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
Study: NCT05966844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfluness and Virtual Reality
Description: They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
Study: NCT04755712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rachianesthesia
Description: Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rachianesthesia
Description: Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride Injection
Description: Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine via pump (patient controlled analgesia)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine via pump (patient controlled analgesia)
Study: NCT06302972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: Hot Pack will be applied at the beginning of the session for 10 minutes. Wall corner stretching exercises, neck isometric exercises and neck stretching exercises will be performed Cold pack will be applied at the end of the session for a few minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM and CCEP
Description: Instrument Assisted Soft Mobilization Technique (IASTM); For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The Comprehensive Corrective Exercise Program (CCEP) will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board
Study: NCT06049914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: 1. Exercise interventions~   * Measuring blood pressure and weight: before starting exercise~  * Flexibility exercises: 5-10 minutes of stretching~  * Strength exercises: Consists of 4 upper body exercises (Biceps Curl, Dips, Front raise, Chest press) and 5 lower body exercises (Leg lateral rotation, Leg extension, Hip abduction, Squat, Heel raise). The intensity of the band starts according to the subject's muscle strength.~  * Aerobic exercise: 5 times a week, home-based, 30 minutes or more each time~2. Nutritional interventions~   * Well nourished: Overall diet check and correction~  * at risk: Correction of diet and intake of up to 2 packs of supplemental protein products per day~  * Malnourished: Correction of diet and intake of up to 3 packs of supplemental protein products per day~  * Nutrition counseling is provided at the beginning of the intervention and high-protein diet composition education is provided~  * Confirm compliance and provide feedback once every 2 weeks
Study: NCT04714593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
Study: NCT05278650

Intervention type: OTHER
Group type: OTHER
Intervention: Senior PharmAssist^TM Program Implementation
Description: Representatives from three diverse communities will participate in co-design workshops to refine the Senior PharmAssistTM (SPA) implementation toolkit, which will then be delivered to agency staff from these partnering communities through a series of learning collaborative sessions to facilitate implementation of SPA core components in each community.~Community champions will be trained to deliver a community-based program to deliver the core components of SPA:~1. Medication Therapy Management (MTM);~2. Medication co-payment assistance;~3. Tailored community referrals; and~4. Medicare insurance counseling
Study: NCT04811469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-174
Description: CBP-174 oral solution, given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution, given once